Sprint Bioscience AB has entered into an agreement to use Lilly Tunelab, Eli Lilly and Co.’s AI-based drug discovery platform, to support work on its research portfolio.
Apertura Gene Therapy LLC has announced its participation in a consortium selected to receive funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE program to develop gene therapies for rare childhood diseases.
Evogene Ltd. and Eleo Inc. have established a strategic scientific collaboration to discover and develop next-generation oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases.
Breezebio Inc. (formerly Genedit Inc.) has entered into a joint research agreement with Ligachem Biosciences Inc. to develop innovative cancer vaccine therapies.
Akari Therapeutics plc has established a strategic research collaboration with Whitehawk Therapeutics Inc. to conduct preclinical studies evaluating Akari’s proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor antibody-drug conjugate platform.
Valerio Therapeutics SA has entered into a binding term-sheet with Abivax SA setting out the principal terms of an exclusive worldwide research and development collaboration to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases.
Rani Therapeutics Holding Inc. has entered into a research and development collaboration with Pegbio Co. Ltd. to explore the delivery of multiple candidates from Pegbio’s obesity and metabolic disease pipeline using Rani’s proprietary Ranipill platform.
Apertura Gene Therapy has entered into a cooperative research and development agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Human Genome Research Institute.
Astex Pharmaceuticals Ltd. has entered into an exclusive, worldwide research collaboration and license agreement with Genentech Inc., a member of the Roche Group, to identify small-molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer.
Insilico will lead AI-driven discovery to identify molecules meeting predefined scientific and early development criteria, while Takeda will apply its global development capabilities to advance selected candidates through clinical validation.
RSS
